Inhibition of prostate cancer growth by estramustine and colchicine

M. Fakih, A. Yagoda, T. Replogle, Kenneth Pienta, K. J. Pienta

Research output: Contribution to journalArticle

Abstract

Hormone-refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT-LyLu (MLL) and human prostate cancer cells (PC- 3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone- refractory prostate cancer requires further investigation.

Original languageEnglish (US)
Pages (from-to)310-315
Number of pages6
JournalProstate
Volume26
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Estramustine
Colchicine
Prostatic Neoplasms
Microtubules
Growth
Hormones
Prostate
Cell Cycle
Adenocarcinoma
Cell Line

Keywords

  • colchicine
  • Dunning Mat-LyLu
  • estramustine
  • PC-3
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Inhibition of prostate cancer growth by estramustine and colchicine. / Fakih, M.; Yagoda, A.; Replogle, T.; Pienta, Kenneth; Pienta, K. J.

In: Prostate, Vol. 26, No. 6, 1995, p. 310-315.

Research output: Contribution to journalArticle

Fakih, M, Yagoda, A, Replogle, T, Pienta, K & Pienta, KJ 1995, 'Inhibition of prostate cancer growth by estramustine and colchicine', Prostate, vol. 26, no. 6, pp. 310-315. https://doi.org/10.1002/pros.2990260606
Fakih, M. ; Yagoda, A. ; Replogle, T. ; Pienta, Kenneth ; Pienta, K. J. / Inhibition of prostate cancer growth by estramustine and colchicine. In: Prostate. 1995 ; Vol. 26, No. 6. pp. 310-315.
@article{25ccb6b9066d499e83afa62a1adcb233,
title = "Inhibition of prostate cancer growth by estramustine and colchicine",
abstract = "Hormone-refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT-LyLu (MLL) and human prostate cancer cells (PC- 3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone- refractory prostate cancer requires further investigation.",
keywords = "colchicine, Dunning Mat-LyLu, estramustine, PC-3, prostate cancer",
author = "M. Fakih and A. Yagoda and T. Replogle and Kenneth Pienta and Pienta, {K. J.}",
year = "1995",
doi = "10.1002/pros.2990260606",
language = "English (US)",
volume = "26",
pages = "310--315",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Inhibition of prostate cancer growth by estramustine and colchicine

AU - Fakih, M.

AU - Yagoda, A.

AU - Replogle, T.

AU - Pienta, Kenneth

AU - Pienta, K. J.

PY - 1995

Y1 - 1995

N2 - Hormone-refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT-LyLu (MLL) and human prostate cancer cells (PC- 3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone- refractory prostate cancer requires further investigation.

AB - Hormone-refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT-LyLu (MLL) and human prostate cancer cells (PC- 3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone- refractory prostate cancer requires further investigation.

KW - colchicine

KW - Dunning Mat-LyLu

KW - estramustine

KW - PC-3

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0029014923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029014923&partnerID=8YFLogxK

U2 - 10.1002/pros.2990260606

DO - 10.1002/pros.2990260606

M3 - Article

VL - 26

SP - 310

EP - 315

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 6

ER -